Delcath Schedules Conference Call to Report 2020 Second Quarter Financial Results
August 06 2020 - 4:01PM
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology
company focused on liver-directed treatment of rare primary and
metastatic cancers, today announced that it will host a conference
call on August 13, 2020 at 4:30 PM Eastern Time to discuss results
for its second quarter ended June 30, 2020.
Conference Call Information
To participate in this event, dial approximately
5 to 10 minutes before the beginning of the call. Please ask for
the Delcath Second Quarter Conference Call when reaching an
operator.
Date: August 13, 2020Time: 4:30 PM Eastern
TimeToll Free: (833) 937-1050International: (845) 403-8302
The call will also be available over the
Internet and accessible at:
https://www.webcaster4.com/Webcast/Page/2475/36568.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional
oncology company focused on the treatment of primary and metastatic
liver cancers. Our investigational product Melphalan Hydrochloride
for Injection for use with the Delcath Hepatic Delivery System
(Melphalan/HDS) – is designed to administer high-dose chemotherapy
to the liver while minimizing systemic exposure and associated side
effects. In addition to the Phase 3 FOCUS Trial, we have initiated
a global Phase 3 clinical trial for intrahepatic cholangiocarcinoma
(ICC) called The ALIGN Trial. We currently are also evaluating
other forms of metastatic liver cancers. Melphalan/HDS has not been
approved by the U.S. Food & Drug Administration (FDA) for sale
in the U.S. In Europe, our system is marketed under the trade name
Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT)
and has been CE Marked and used at major medical centers to treat a
wide range of cancers of the liver. CHEMOSAT is being marketed
under an exclusive licensing agreement with medac GmbH, a privately
held multi-national pharmaceutical company headquartered in Germany
that specializes in the treatment and diagnosis of oncological,
urological and autoimmune diseases.
Contact:
Hayden IRJames
Carbonara(646)-755-7412james@haydenir.com
Brett Maas(646) 536-7331brett@haydenir.com
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Apr 2023 to Apr 2024